BACKGROUND: Transporter associated with antigen processing (TAP), a member of the ATP-binding cassette transporter super family, is composed of two integral membrane proteins, TAP-1 and TAP-2. The TAP gene product is involved in the processing of endogenous peptides that bind to MHC class I molecules. Mutations and/or polymorphism within these genes could alter the efficacy of the immune response which might be relevant for the development of autoimmune diseases and cancer. METHODS: DNA was isolated from peripheral blood sample of 200 patients with cervical cancer and 200 healthy controls. TAP1 and TAP2 allele polymorphism were determined by polymerase chain reaction. RESULT: Significant protective OR (OR = 0.22 95% CI = 0.09-0.51, P < 0.001-OR = 0.47, 95% CI = 0.24-0.92, P = 0.02) was observed for GG and combined AG+GG genotypes of TAP2 in patients with SCC respectively. Similarly, such genotypes (GG, AG+GG) appeared same OR for patient with cervical cancer in study group (OR = 0.12, 95% CI = 0.04-0.39-P < 0.001-OR = 0.5 ,95% CI = 0.25-0.95-P = 0.03). There was decrease risk of cervical cancer in user of oral contraceptive with AG and GG genotypes of TAP2 (OR = 0.55, 95% Cl = 0.41-0.73, P = 0.002, OR = 0.09, 95% CI = 0.02-0.36, P < 0.001) respectively. In case of TAP1 gene all allelic polymorphisms showed a decrease OR in patients with cervical cancer in passive smokers and user of oral contraceptives, though, no significant CONCLUSION: Thus, TAP1 and TAP2 genes polymorphism are not linked to cervical carcinoma, since no association was found between a particular genotype and the disease.
BACKGROUND:Transporter associated with antigen processing (TAP), a member of the ATP-binding cassette transporter super family, is composed of two integral membrane proteins, TAP-1 and TAP-2. The TAP gene product is involved in the processing of endogenous peptides that bind to MHC class I molecules. Mutations and/or polymorphism within these genes could alter the efficacy of the immune response which might be relevant for the development of autoimmune diseases and cancer. METHODS: DNA was isolated from peripheral blood sample of 200 patients with cervical cancer and 200 healthy controls. TAP1 and TAP2 allele polymorphism were determined by polymerase chain reaction. RESULT: Significant protective OR (OR = 0.22 95% CI = 0.09-0.51, P < 0.001-OR = 0.47, 95% CI = 0.24-0.92, P = 0.02) was observed for GG and combined AG+GG genotypes of TAP2 in patients with SCC respectively. Similarly, such genotypes (GG, AG+GG) appeared same OR for patient with cervical cancer in study group (OR = 0.12, 95% CI = 0.04-0.39-P < 0.001-OR = 0.5 ,95% CI = 0.25-0.95-P = 0.03). There was decrease risk of cervical cancer in user of oral contraceptive with AG and GG genotypes of TAP2 (OR = 0.55, 95% Cl = 0.41-0.73, P = 0.002, OR = 0.09, 95% CI = 0.02-0.36, P < 0.001) respectively. In case of TAP1 gene all allelic polymorphisms showed a decrease OR in patients with cervical cancer in passive smokers and user of oral contraceptives, though, no significant CONCLUSION: Thus, TAP1 and TAP2 genes polymorphism are not linked to cervical carcinoma, since no association was found between a particular genotype and the disease.
Authors: B Seliger; A Höhne; D Jung; M Kallfelz; A Knuth; E Jaeger; H Bernhard; F Momburg; R Tampé; C Huber Journal: Exp Hematol Date: 1997-07 Impact factor: 3.084
Authors: Christine F W Vermeulen; Ekaterina S Jordanova; Natalja T ter Haar; Sandra M Kolkman-Uljee; Noel F de Miranda; Soldano Ferrone; Alexander A W Peters; Gert Jan Fleuren Journal: Gynecol Oncol Date: 2007-03-26 Impact factor: 5.482
Authors: T Tsukui; A Hildesheim; M H Schiffman; J Lucci; D Contois; P Lawler; B B Rush; A T Lorincz; A Corrigan; R D Burk; W Qu; M A Marshall; D Mann; M Carrington; M Clerici; G M Shearer; D P Carbone; D R Scott; R A Houghten; J A Berzofsky Journal: Cancer Res Date: 1996-09-01 Impact factor: 12.701
Authors: Cornelia L Trimble; Jeanine M Genkinger; Alyce E Burke; Sandra C Hoffman; Kathy J Helzlsouer; Marie Diener-West; George W Comstock; Anthony J Alberg Journal: Obstet Gynecol Date: 2005-01 Impact factor: 7.661
Authors: A Hildesheim; M H Schiffman; P E Gravitt; A G Glass; C E Greer; T Zhang; D R Scott; B B Rush; P Lawler; M E Sherman Journal: J Infect Dis Date: 1994-02 Impact factor: 5.226
Authors: G Y Ho; P R Palan; J Basu; S L Romney; A S Kadish; M Mikhail; S Wassertheil-Smoller; C Runowicz; R D Burk Journal: Int J Cancer Date: 1998-11-23 Impact factor: 7.396
Authors: Akash M Mehta; Merel Mooij; Ivan Branković; Sander Ouburg; Servaas A Morré; Ekaterina S Jordanova Journal: J Immunol Res Date: 2017-02-09 Impact factor: 4.818
Authors: Camilla Natter; Stephan Polterauer; Jasmin Rahhal-Schupp; Dan Cacsire Castillo-Tong; Sophie Pils; Paul Speiser; Robert Zeillinger; Georg Heinze; Christoph Grimm Journal: Dis Markers Date: 2013-07-28 Impact factor: 3.434